ruxolitinib在血液肿瘤中的临床应用进展

随着JAK/STAT通路异常在骨髓增生性肿瘤（myeloproliterative neoplasms，MPN）、急性白血病（acute leukemia，AL）、多发性骨髓瘤（multiple myeloma，MM）、噬血细胞综合征（hemophagocytic syndrome，HPS）等多种血液系统疾病中被发现，一系列针对JAK/STAT途径的靶向药物被研发，其中一种JAK1/JAK2抑制剂芦可替尼（ruxolitinib）已被美国食品药品监督管理局（FDA）批准用于治疗骨髓纤维化（myelofibrosis，MF）和真性红细胞增多症（polycythemia vera，PV）。ruxolitinib治疗其他血液系统疾病，如AL、MM和HPS均取得了较好的疗效，为血液病患者带来新的希望。本文将就ruxolitinib在上述疾病中的作用机制和临床研究结果予以综述。 

Advances in clinical application of ruxolitinib for hematologic malignancies

Because the pathogenesis of some hematologic malignancies (e.g., myeloproliferative disease, MPN; acute leukemia, AL; multiple myeloma, MM; and (hemophagocytic syndrome, HPS) involve abnormalities in the JAK/STAT pathway, a series of drugs that target the JAK/STAT pathway has been the subject of clinical trials. Ruxolitinib (also known as INCB018424), an inhibitor of the JAK1/2 pathway, was approved as the treatment choice for myelofibrosis (MF) and polycythemia vera (PV) by the U.S. Food and Drug Administration (FDA) in 2011. Moreover, some studies have shown that ruxolitinib can achieve exciting clinical results in the treatment of AL, MM, and HLH, making it a potential choice of treatment for those diseases. In this review, we summarize the advances in ruxolitinib therapy with regard to research and clinical results for the above-mentioned hematologic malignancies.